Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 2 infusions of a 1 dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of infusion.
Epistemonikos ID: de252a72a0da05307b94e05956cbfafa362adcf7
First added on: May 07, 2024